Cleerly
Cleerly is a digital healthcare company that uses AI-based technology to transform the diagnosis and treatment of heart disease, focusing on precise identification and management of atherosclerosis through advanced imaging and personalized care pathways.
Company History
Cleerly, a digital healthcare company, was recognized for its innovation in the field of heart disease treatment when it was named to the 2021 CB Insights Digital Health 150 and Fierce Medtech's 2021’s Fierce 15 Med Tech Companies. Additionally, Cleerly was named to the NYC Digital Health 100 by the New York City Health Business Leaders. Cleerly launched with a $43 million Series B funding aimed at establishing a new standard of care for heart disease.
Cleerly's Services
Cleerly offers an AI-based digital care platform that integrates with coronary computed tomography angiography (CCTA) imaging to help clinicians accurately identify and define atherosclerosis earlier. Their digital cardiovascular care management program includes innovative digital and print tools that transform complex imaging data into actionable clinical insights. The platform empowers providers to analyze, characterize, and quantify different types of plaque, moving beyond traditional measures of heart disease. Cleerly's AI-enabled care pathway provides a simpler, faster, and more precise evaluation and reporting tailored to stakeholders' needs.
Clinical Trials and Studies
Cleerly's technology has been validated through various clinical trials demonstrating high diagnostic performance. One prominent example is the TRANSFORM clinical trial, which aims to engage 7,500 patients at over 100 sites over a five-year period. This randomized trial targets patients with pre-diabetes, type 2 diabetes, or metabolic syndrome and no symptoms of heart disease to prove that personalized care strategy based on Cleerly analysis is superior to traditional cardiovascular risk factors. Cleerly's AI-QCT technology has shown a high agreement with invasive methods like intravascular ultrasound (IVUS) for coronary artery disease evaluation.
Innovative Technology and Products
Cleerly’s technology measures atherosclerosis through plaque build-up in heart arteries, rather than relying on indirect markers like risk factors and disease symptoms. One of Cleerly’s key technologies, Track Your Plaque™, allows evaluation of changes in plaque burden over time. Cleerly’s method for analyzing CTA imaging provides more comprehensive information compared to traditional CTAs. Cleerly 2.2.0, their latest product release, includes several user experience refinements and introduces three new high-value tools. The company's products and services are protected under multiple U.S. patents.